Microarray Market Report 2026

The microarray market size has grown strongly in recent years. It will grow from $5.62 billion in 2025 to $6.17 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to growing adoption of gene expression profiling, advances in dna sequencing technologies, increased use of microarrays in cancer research, expansion of drug discovery programs, rising prevalence of genetic disorders.

The microarray market size is expected to see rapid growth in the next few years. It will grow to $9.1 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, advancements in bioinformatics processing tools, rising integration of automation in microarray workflows, expanding applications in toxicological testing, growing need for high-throughput genomic analysis. Major trends in the forecast period include genomics-driven microarray optimization, cloud-based data processing for microarray analysis, AI-enhanced gene expression interpretation, automated microarray manufacturing systems, iot-enabled sample tracking and monitoring.

The increasing incidence of cancer cases is anticipated to drive the growth of the microarray market in the coming years. Cancer is a condition in which certain cells in the body grow uncontrollably and spread to other parts of the body. The rise in cancer cases is largely attributed to the growing prevalence of established cancer risk factors, exposure to specific chemicals, an aging population, and common cancers such as breast, lung, and bronchial cancers, where microarray technology enables researchers to identify changes in gene expression potentially linked to cancer. For example, in January 2023, the American Cancer Society, a US-based voluntary health organization, reported that approximately 9,910 children under the age of 15 in the US were diagnosed with cancer, and around 1,040 children under 15 died from the disease in 2023. Consequently, the rising number of cancer cases is propelling the growth of the microarray market.

Key players in the microarray market are focusing on the development of chromosomal microarrays to strengthen their market presence. Chromosomal Microarray Analysis (CMA) represents a leading-edge technology in genomic medicine, advancing diagnostic capabilities significantly. For instance, in August 2023, Thermo Fisher Scientific, Inc., a US-based provider of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services, introduced the Applied Biosystems CytoScan HD Accel array, a new chromosomal microarray aimed at enhancing productivity, efficiency, and profitability in cytogenetic research laboratories. This state-of-the-art array offers an industry-leading two-day turnaround time, marking a notable advancement in the field. The Applied Biosystems CytoScan HD Accel array performs a thorough analysis of the entire human genome. With improved coverage of over 5,000 critical genomic regions, it delivers valuable insights into chromosomal variations. This advanced technology is highly beneficial for various applications, including prenatal and postnatal research, as well as cancer-related studies.

In May 2024, Bruker, a US-based provider of analytical instrumentation and scientific solutions, acquired NanoString Business for an undisclosed sum. The acquisition of NanoString's business by Bruker is intended to reinforce Bruker's presence in the life sciences sector and expand its portfolio of analytical tools and solutions. NanoString Business is a US-based biotechnology firm that produces DNA and protein microarrays and biosensors.

Major companies operating in the microarray market are Agilent Technologies Inc., Arrayit Corporation, Bio-Rad Laboratories Inc., Danaher Corporation, GE Healthcare Inc., Illumina Inc., Merck KGaA, Microarray Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., Molecular Devices LLC, RayBiotech Life Inc., Schott Minifab AG, Full Moon Biosystems Inc., CapitalBio Technology Co. Ltd., Roche Diagnostics Ltd., Affymetrix Inc., SCIENION AG, NextGen Sciences Inc., PathogenDx Inc., BioGenomics Limited, BioMicro Systems Inc., Biostatus Limited, Biotechrabbit GmbH, INanoBio Inc.

North America was the largest region in the microarray market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global microarray market report during the forecast period. The regions covered in the microarray market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microarray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on electronic components, laboratory instruments, and imported reagents have increased the production and procurement costs of microarray systems, especially in regions heavily dependent on international suppliers. These tariffs particularly impact DNA microarray and protein microarray segments, along with markets in Asia-Pacific and Europe. While the costs and supply delays hinder adoption, they also stimulate local manufacturing and innovation, encouraging regional suppliers to develop cost-effective microarray products and reduce import dependency.

The microarray market research report is one of a series of new reports that provides microarray market statistics, including microarray industry global market size, regional shares, competitors with a microarray market share, detailed microarray market segments, market trends and opportunities, and any further data you may need to thrive in the microarray industry. This microarray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Microarray is a widely used laboratory technique that involves attaching a large number of recognized nucleic acid fragments, ranging from tens of thousands to millions, onto a solid surface called a chip. It is commonly employed for various applications in scientific and medical research, such as detecting specific DNA sequences and analyzing gene expression.

The primary forms of microarrays include DNA microarrays, protein microarrays, and others. A DNA microarray consists of numerous small DNA spots affixed to a solid substrate and is utilized to determine whether a gene mutation, such as in BRCA1 or BRCA2, exists in an individual's DNA. These microarrays are applied in disease diagnosis, cancer genomics, drug discovery, genomic sequencing, expression analysis, toxicology studies, and other uses by pharmaceutical companies, biotechnology firms, academic institutions, research laboratories, and additional end-users.

The microarray market consists of revenues earned by entities by providing services such as genotyping and methylation array services, analytical protein microarray, functional protein array, reverse-phase protein array, and peptide microarray. The value of associated goods sold by the service provider or incorporated into the service providing is included in the market value. The microarray market also includes sales of microarray slides or chips and priming, microarray fluorescence and colorimetric scanners, printers, hybridization stations or DNA and RNA assays, whole genome sequencing, cDNA Microarray, BAC microarray, oligo microarray, which are used in providing microarray services. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.